Loading
A phase 2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.
Ribociclib (LEE011) Rollover Study for Continued Access is a phase 2 interventional study registered as NCT02934568 by Novartis Pharmaceuticals, with 22 participants enrolled, started 2016-12-15 and due to reach its primary completion in 2027-02-01. Interventions recorded: LEE011.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/